{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:25:29Z","timestamp":1793042729754,"version":"4.5.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA160762"],"award-info":[{"award-number":["CA160762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Glioblastoma (GBM) is one of the most lethal cancers, having a poor prognosis and a median survival of only about 15 months with standard treatment (surgery, radiation, and chemotherapy), which has not been significantly extended in decades. GBM demonstrates remarkable cellular heterogeneity, with glioblastoma stem-like cells (GSCs) at the apex. GSCs are a subpopulation of GBM cells that possess the ability to self-renew, differentiate, initiate tumor formation, and manipulate the tumor microenvironment (TME). GSCs are no longer considered a static population of cells with specific markers but are quite flexible phenotypically and in driving tumor heterogeneity and therapeutic resistance. In light of these features, they are a critical target for successful GBM therapy. Oncolytic viruses, in particular oncolytic herpes simplex viruses (oHSVs), have many attributes for therapy and are promising agents to target GSCs. oHSVs are genetically-engineered to selectively replicate in and kill cancer cells, including GSCs, but not normal cells. Moreover, oHSV can induce anti-tumor immune responses and synergize with other therapies, such as chemotherapy, DNA repair inhibitors, and immune checkpoint inhibitors, to potentiate treatment effects and reduce GSC populations that are partly responsible for chemo- and radio-resistance. Herein, we present an overview of GSCs, activity of different oHSVs, clinical trial results, and combination strategies to enhance efficacy, including therapeutic arming of oHSV. Throughout, the therapeutic focus will be on GSCs and studies specifically targeting these cells. Recent clinical trials and approval of oHSV G47\u0394 in Japan for patients with recurrent glioma demonstrate the efficacy and promise of oHSV therapy.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1206111","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:29:38Z","timestamp":1685510978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells"],"prefix":"10.3389","volume":"13","author":[{"given":"Kimia","family":"Kardani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Sanchez Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"B140","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/gt.2011.61","article-title":"Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1","volume":"18","author":"Advani","year":"2011","journal-title":"Gene Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","article-title":"HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors","volume":"16","author":"Ahmed","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1002\/j.1460-2075.1996.tb00689.x","article-title":"Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47","volume":"15","author":"Ahn","year":"1996","journal-title":"EMBO J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1038\/s41388-019-0737-2","article-title":"Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model","volume":"38","author":"Alessandrini","year":"2019","journal-title":"Oncogene"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3390\/v13091677","article-title":"Specificity, safety, efficacy of EGFRvIII-retargeted oncolytic HSV for xenotransplanted human glioblastoma","volume":"13","author":"Appolloni","year":"2021","journal-title":"Viruses"},{"key":"B24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11060-012-0878-4","article-title":"Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines","volume":"109","author":"Beier","year":"2012","journal-title":"J. Neurooncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.stem.2019.11.015","article-title":"Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma","volume":"26","author":"Bhaduri","year":"2020","journal-title":"Cell Stem Cell."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq032","article-title":"Sensitivity to temozolomide in brain tumor initiating cells","author":"Blough","year":"2010","journal-title":"Neuro Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe2550","article-title":"OAS1\/RNase l executes RIG-I ligand-dependent tumor cell apoptosis","volume":"6","author":"Boehmer","year":"2021","journal-title":"Sci. Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.695325","article-title":"Critical view of novel treatment strategies for glioblastoma: failure and success of resistance mechanisms by glioblastoma cells","volume":"9","author":"Burster","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-15-2888","article-title":"Survival and proliferation of neural progenitor-derived glioblastomas under hypoxic stress is controlled by a CXCL12\/CXCR4 autocrine-positive feedback mechanism","volume":"23","author":"Calinescu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1593\/neo.08814","article-title":"Tumor progression and oncogene addiction in a PDGF-b-induced model of gliomagenesis","volume":"10","author":"Calzolari","year":"2008","journal-title":"Neoplasia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/v8030063","article-title":"Retargeting strategies for oncolytic herpes simplex viruses","volume":"8","author":"Campadelli-Fiume","year":"2016","journal-title":"Viruses"},{"key":"B94","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1128\/JVI.79.14.8707-8715.2005","article-title":"Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection","volume":"79","author":"Cassady","year":"2005","journal-title":"J. Virol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2017.02.001","article-title":"Pre-clinical assessment of C134, a chimeric oncolytic herpes simplex virus, in mice and non-human primates","volume":"5","author":"Cassady","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2326-6066.CIR-17-0675","article-title":"Disruption of IFN-I signaling promotes HER2\/Neu tumor progression and breast cancer stem cells","volume":"6","author":"Castiello","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"423","DOI":"10.20517\/jtgg.2021.31","article-title":"Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus","volume":"5","author":"Chambers","year":"2021","journal-title":"J. Transl. Genet. Genom."},{"key":"B145","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1158\/1078-0432.CCR-11-1762","article-title":"Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts","volume":"17","author":"Cheema","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/glia.23883","article-title":"Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade","volume":"68","author":"Chen","year":"2020","journal-title":"Glia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","article-title":"Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth","volume":"153","author":"Cheng","year":"2013","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","article-title":"Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene","volume":"17","author":"Chiocca","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/cancers13020230","article-title":"A set of cell lines derived from a genetic murine glioblastoma model recapitulates molecular and morphological characteristics of human tumors","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B90","unstructured":"Daiichi sankyo launches DELYTACT\u00ae oncolytic virus G47\u0394 in Japan2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/neuonc\/nov143","article-title":"Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors","volume":"18","author":"Davis","year":"2016","journal-title":"Neuro Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: a review on the impact of treatment modalities","volume":"18","author":"Delgado-L\u00f3pez","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/v13010017","article-title":"\"Non-essential\" proteins of HSV-1 with essential roles In vivo: a comprehensive review","volume":"13","author":"Dogrammatzis","year":"2020","journal-title":"Viruses"},{"key":"B60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbrc.2017.07.098","article-title":"The effects of type I interferon on glioblastoma cancer stem cells","volume":"491","author":"Du","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1002\/ijc.30929","article-title":"Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models","volume":"141","author":"Esaki","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/neuonc\/not223","article-title":"Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype","volume":"16","author":"Fouse","year":"2014","journal-title":"Neuro Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"13930","DOI":"10.1038\/s41598-018-32353-x","article-title":"Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with nectin-1 expression","volume":"8","author":"Friedman","year":"2018","journal-title":"Sci. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1593\/tlo.12115","article-title":"Hypoxia moderates \u03b3(1)34.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures","volume":"5","author":"Friedman","year":"2012","journal-title":"Trans. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/gt.2014.107","article-title":"\u03b3134.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia","volume":"22","author":"Friedman","year":"2015","journal-title":"Gene Ther."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128456","article-title":"Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry","volume":"6","author":"Galdieri","year":"2021","journal-title":"JCI Insight"},{"key":"B111","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/mt.2012.22","article-title":"Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma","volume":"20","author":"Gambini","year":"2012","journal-title":"Mol. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1158\/0008-5472.CAN-06-2698","article-title":"Characterization of microRNA expression levels and their biological correlates in human cancer cell lines","volume":"67","author":"Gaur","year":"2007","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coviro.2016.08.007","article-title":"Retargeting of herpes simplex virus (HSV) vectors","volume":"21","author":"Goins","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.614295","article-title":"Evolution of experimental models in the study of glioblastoma: toward finding efficient treatments","volume":"10","author":"G\u00f3mez-Oliva","year":"2020","journal-title":"Front. Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1158\/0008-5472.CAN-15-0894","article-title":"TGF\u03b2 treatment enhances glioblastoma virotherapy by inhibiting the innate immune response","volume":"75","author":"Han","year":"2015","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival","volume":"11","author":"Harrow","year":"2004","journal-title":"Gene Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.3390\/cancers14153743","article-title":"Molecular pathways and genomic landscape of glioblastoma stem cells: opportunities for targeted therapy","volume":"14","author":"Hersh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.3390\/v13091740","article-title":"In situ cancer vaccination and immunovirotherapy using oncolytic HSV","volume":"13","author":"Jahan","year":"2021","journal-title":"Viruses"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/ijc.30811","article-title":"Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus","volume":"141","author":"Jahan","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.36255\/exonpublications.gliomas.2021.chapter2","article-title":"Mouse models of experimental glioblastoma","volume-title":"Gliomas","author":"Jin","year":"2021"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/cns.12.42","article-title":"Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors","volume":"2","author":"Kanai","year":"2013","journal-title":"CNS Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/jnci\/djr509","article-title":"Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells","volume":"104","author":"Kanai","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-10-3142","article-title":"A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase\/Akt pathway inhibitors to target glioblastoma stem cells","volume":"17","author":"Kanai","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1128\/JVI.00017-12","article-title":"Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors","volume":"86","author":"Kanai","year":"2012","journal-title":"J. Virol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/v13071408","article-title":"Oncolytic HSV: underpinnings of tumor susceptibility","volume":"13","author":"Kangas","year":"2021","journal-title":"Viruses"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene laherparepvec: moving from first-In-Class to best-In-Class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.omto.2020.08.004","article-title":"Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability","volume":"18","author":"Kennedy","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat. Commun."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604121","article-title":"Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy","volume":"10","author":"Klein","year":"2020","journal-title":"Front. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell."},{"key":"B13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","article-title":"Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines","volume":"9","author":"Lee","year":"2006","journal-title":"Cancer Cell."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1535-7163.MCT-18-0953","article-title":"Enhancing therapeutic efficacy of oncolytic herpes simplex virus-1 with integrin \u03b21 blocking antibody OS2966","volume":"18","author":"Lee","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.1073\/pnas.94.15.7891","article-title":"The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus","volume":"94","author":"Leopardi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11060-014-1612-1","article-title":"Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma","volume":"121","author":"Lu","year":"2015","journal-title":"J. Neurooncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-017-2379-y","article-title":"Molecular markers in glioma","volume":"134","author":"Ludwig","year":"2017","journal-title":"J. Neurooncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-Shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1099\/0022-1317-72-3-631","article-title":"Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence","volume":"72","author":"MacLean","year":"1991","journal-title":"J. Gen. Virol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1128\/JVI.06998-11","article-title":"Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12","volume":"86","author":"Markert","year":"2012","journal-title":"J. Virol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol. Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/mt.2014.177","article-title":"Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV","volume":"23","author":"Mazzacurati","year":"2015","journal-title":"Mol. Ther."},{"key":"B169","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1158\/0008-5472.CAN-10-2353","article-title":"Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis","volume":"70","author":"Mazzoleni","year":"2010","journal-title":"Cancer Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"82","author":"Menotti","year":"2008","journal-title":"J. Virol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/1078-0432.CCR-21-2636","article-title":"Immune activity and response differences of oncolytic viral therapy in recurrent glioblastoma: gene expression analyses of a phase IB study","volume":"28","author":"Miller","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B71","first-page":"3963","article-title":"Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant","volume":"54","author":"Mineta","year":"1994","journal-title":"Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1002\/j.1460-2075.1996.tb00853.x","article-title":"A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function","volume":"15","author":"Mohr","year":"1996","journal-title":"EMBO J."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1128\/JVI.73.4.3375-3385.1999","article-title":"A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function","volume":"73","author":"Mulvey","year":"1999","journal-title":"J. Virol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/biology10090856","article-title":"The yin and yang of type I IFNs in cancer promotion and immune activation","volume":"10","author":"Musella","year":"2021","journal-title":"Biol. (Basel)"},{"key":"B149","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1172\/JCI80713","article-title":"Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma","volume":"125","author":"Nakashima","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B147","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/OV.S66081","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Nakashima","year":"2015","journal-title":"Oncolytic Virother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1158\/1078-0432.CCR-17-2954","article-title":"Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma","volume":"24","author":"Nakashima","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040856","article-title":"Pathogenetic features and current management of glioblastoma","volume":"13","author":"Nguyen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/cells9020400","article-title":"Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OV.S268426","article-title":"The current state of oncolytic herpes simplex virus for glioblastoma treatment","volume":"10","author":"Nguyen","year":"2021","journal-title":"Oncolytic Virother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/NEN.0000000000000210","article-title":"Targeting hypoxia-inducible factor 1alpha in a new orthotopic model of glioblastoma recapitulating the hypoxic tumor microenvironment","volume":"74","author":"Nigim","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw229","article-title":"Rad51 degradation: role in oncolytic virus-Poly(ADP-Ribose) polymerase inhibitor combination therapy in glioblastoma","volume":"109","author":"Ning","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"B150","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-12-3588","article-title":"DNA Demethylating agents synergize with oncolytic HSV1 against malignant gliomas","volume":"19","author":"Okemoto","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2020.11.FOCUS20844","article-title":"Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas","volume":"50","author":"Omar","year":"2021","journal-title":"Neurosurg. Focus."},{"key":"B93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chom.2006.12.001","article-title":"HSV-1 ICP34.5 confers neurovirulence by targeting the beclin 1 autophagy protein","volume":"1","author":"Orvedahl","year":"2007","journal-title":"Cell Host Microbe"},{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-19-3420","article-title":"Oncolytic HSV-infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition","volume":"26","author":"Otani","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"B167","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with Recurrent\/Progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071367","article-title":"Checkpoint inhibitors as high-grade gliomas treatment: state of the art and future perspectives","volume":"10","author":"Persico","year":"2021","journal-title":"J. Clin. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2617030","DOI":"10.1155\/2019\/2617030","article-title":"The genetic landscape of human glioblastoma and matched primary cancer stem cells reveals intratumour similarity and intertumour heterogeneity","volume":"2019","author":"Pesenti","year":"2019","journal-title":"Stem Cells Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e00246","DOI":"10.1128\/JVI.00246-18","article-title":"Restriction of replication of oncolytic herpes simplex virus with a deletion of gamma34.5 in glioblastoma stem-like cells","volume":"92","author":"Peters","year":"2018","journal-title":"J. Virol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/mto.2015.10","article-title":"Designing herpes viruses as oncolytics","volume":"2","author":"Peters","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nature05349","article-title":"Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells","volume":"444","author":"Piccirillo","year":"2006","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/hum.1997.8.5-533","article-title":"A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors","volume":"8","author":"Pyles","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.gt.3301184","article-title":"Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma","volume":"7","author":"Rampling","year":"2000","journal-title":"Gene Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/cgt.2012.62","article-title":"Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice","volume":"19","author":"Reisoli","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nature09557","article-title":"Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells","volume":"468","author":"Ricci-Vitiani","year":"2010","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.virol.2015.02.036","article-title":"The 3 facets of regulation of herpes simplex virus gene expression: a critical inquiry","author":"Roizman","year":"2015","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/neuonc\/now160","article-title":"Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors","volume":"19","author":"Rosenberg","year":"2017","journal-title":"Neuro Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/humc.2013.201","article-title":"Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates","volume":"25","author":"Roth","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1038\/s41467-021-23817-2","article-title":"P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas","volume":"12","author":"Rousso-Noori","year":"2021","journal-title":"Nat. Commun."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.558381","article-title":"Engineering three-dimensional tumor models to study glioma cancer stem cells and tumor microenvironment","volume":"14","author":"Ruiz-Garcia","year":"2020","journal-title":"Front. Cell Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1358\/dof.2015.040.11.2383070","article-title":"Exploring the antitumor effect of virus in malignant glioma","volume":"40","author":"Saha","year":"2015","journal-title":"Drugs Future"},{"key":"B160","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000345","article-title":"Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B157","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1158\/1078-0432.CCR-17-1717","article-title":"Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models","volume":"24","author":"Saha","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.omto.2022.06.002","article-title":"Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4(+) GBM cells: a proof of principle","volume":"26","author":"Sanchez Gil","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00457-z","article-title":"An armed oncolytic virus for GBM destruction","volume":"3","author":"Sanchez Gil","year":"2022","journal-title":"Nat. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1016\/j.celrep.2016.11.056","article-title":"Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition","volume":"17","author":"Segerman","year":"2016","journal-title":"Cell Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/sj.gt.3302942","article-title":"Enhanced antiglioma activity of chimeric HCMV\/HSV-1 oncolytic viruses","volume":"14","author":"Shah","year":"2007","journal-title":"Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"19098","DOI":"10.1073\/pnas.1813495116","article-title":"Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments","volume":"116","author":"Shen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B15","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.1016030108","article-title":"Transdifferentiation of glioblastoma cells into vascular endothelial cells","volume":"108","author":"Soda","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.mcpro.2022.100247","article-title":"Discovery proteomics analysis determines that driver oncogenes suppress antiviral defense pathways through reduction in interferon-\u03b2 autocrine stimulation","volume":"21","author":"Solomon","year":"2022","journal-title":"Mol. Cell. Proteomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"Jama"},{"key":"B36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cell.2014.02.030","article-title":"Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells","volume":"157","author":"Suva","year":"2014","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ccell.2020.04.001","article-title":"The glioma stem cell model in the era of single-cell genomics","volume":"37","author":"Suv\u00e0","year":"2020","journal-title":"Cancer Cell."},{"key":"B92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4161\/auto.2176","article-title":"PKR-dependent autophagic degradation of herpes simplex virus type 1","volume":"2","author":"Talloczy","year":"2006","journal-title":"Autophagy"},{"key":"B134","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/mt.2012.175","article-title":"Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors","volume":"21","author":"Tamura","year":"2013","journal-title":"Mol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41598-018-37437-2","article-title":"Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy","volume":"9","author":"Tanaka","year":"2019","journal-title":"Sci. Rep."},{"key":"B120","unstructured":"Australian Public assessment report for talimogene laherparepvec 20162016"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat. Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/10430349950018832","article-title":"Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity","volume":"10","author":"Toda","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1089\/10430349950016483","article-title":"Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus","volume":"10","author":"Todo","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"B153","doi-asserted-by":"publisher","first-page":"551","DOI":"10.18632\/oncotarget.26560","article-title":"Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy","volume":"10","author":"Toll","year":"2019","journal-title":"Oncotarget"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/1535-7163.MCT-18-0799","article-title":"Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways","volume":"18","author":"Tomita","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/mt.2012.211","article-title":"Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus","volume":"21","author":"Uchida","year":"2013","journal-title":"Mol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40478-021-01124-7","article-title":"Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration","volume":"9","author":"Uneda","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","article-title":"Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors","volume":"69","author":"Wakimoto","year":"2009","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/nor195","article-title":"Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells","volume":"14","author":"Wakimoto","year":"2012","journal-title":"Neuro Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09624","article-title":"Glioblastoma stem-like cells give rise to tumour endothelium","volume":"468","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1412767111","article-title":"Direct activation of RIP3\/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2018.03.011","article-title":"Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression","volume":"22","author":"Wang","year":"2018","journal-title":"Cell Stem Cell."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010019","article-title":"Immunocompetent mouse models in the search for effective immunotherapy in glioblastoma","volume":"13","author":"Wouters","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/neuonc\/noaa275","article-title":"Tumor cell network integration in glioma represents a stemness feature","volume":"23","author":"Xie","year":"2021","journal-title":"Neuro Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.devcel.2021.12.007","article-title":"Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy","volume":"57","author":"Xie","year":"2022","journal-title":"Dev. Cell."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4302","article-title":"An oncolytic herpesvirus expressing e-cadherin improves survival in mouse models of glioblastoma","volume":"37","author":"Xu","year":"2018","journal-title":"Nat. Biotechnol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/neuonc\/noz079","article-title":"Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo","volume":"21","author":"Yoo","year":"2019","journal-title":"Neuro Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1593\/neo.13158","article-title":"Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models","volume":"15","author":"Zhang","year":"2013","journal-title":"Neoplasia"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095872","article-title":"Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/17460441.2021.1850689","article-title":"The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy","volume":"16","author":"Zhang","year":"2021","journal-title":"Expert Opin. Drug Discov"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1206111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:29:42Z","timestamp":1685510982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1206111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":168,"alternative-id":["10.3389\/fcimb.2023.1206111"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1206111","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"1206111"}}